The CTC has established two labs to cope with the growing need for in-house molecular and biochemical biomarker research. The labs support cardiovascular, neo-natal and diabetes trials. Prof Alicia Jenkins and A/Prof Hardikar are world-renowned leading experts in this area and have enabled the development of a collaborative network with national and international centres.

The labs help to facilitate “bench-to-bedside” (and reverse) research in type 1 and type 2 diabetes, including pancreating islet cell biology, micro- and macrovascular complication of diabetes and novel therapies (islet transplantation, artificial pancreas). They also provide input in the analysis of samples from various clinical trials run within Australia and overseas.

Samples from the trials are stored and anlaysed in our labs. These biospecimens are used in translational research studies to seek biomarkers. Biomarkers are biological flags that may help to select patients most likely to benefit from a treatment, forecast survival or to spare particular patients from treatment toxicities.

The biomarkers can also be used as a tool in precision medicine - to select the right treatment, delivered at the right time for the individual patient.